Abeona Therapeutics (NASDAQ:ABEO) Now Covered by Analysts at Oppenheimer

Stock analysts at Oppenheimer began coverage on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research note issued on Wednesday,Briefing.com Automated Import reports. The firm set an “outperform” rating and a $16.00 price target on the biopharmaceutical company’s stock. Oppenheimer’s price target would suggest a potential upside of 215.58% from the stock’s current price.

Several other analysts have also recently issued reports on the company. StockNews.com cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 22nd. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.50.

Abeona Therapeutics Trading Down 0.4 %

Shares of Abeona Therapeutics stock opened at $5.07 on Wednesday. Abeona Therapeutics has a fifty-two week low of $3.05 and a fifty-two week high of $9.01. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The company has a market capitalization of $220.40 million, a P/E ratio of -1.88 and a beta of 1.79. The company has a fifty day moving average of $5.59 and a 200 day moving average of $5.85.

Institutional Trading of Abeona Therapeutics

A number of institutional investors have recently bought and sold shares of ABEO. Rosalind Advisors Inc. raised its stake in shares of Abeona Therapeutics by 4.7% in the third quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock valued at $11,578,000 after acquiring an additional 82,000 shares during the period. GSA Capital Partners LLP grew its holdings in Abeona Therapeutics by 54.3% during the 3rd quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock valued at $607,000 after purchasing an additional 33,831 shares during the last quarter. Charles Schwab Investment Management Inc. bought a new position in Abeona Therapeutics during the 3rd quarter valued at about $151,000. Citigroup Inc. raised its position in Abeona Therapeutics by 10.1% in the 3rd quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock worth $3,897,000 after purchasing an additional 56,332 shares during the period. Finally, Western Standard LLC lifted its stake in shares of Abeona Therapeutics by 7.0% during the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock worth $10,732,000 after acquiring an additional 110,998 shares during the last quarter. 80.56% of the stock is currently owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.